jofinЖурнал инфектологииJournal Infectology2072-6732IPO “АIDSSPbR"10.22625/2072-6732-2022-14-5-35-40jofin-1424Research ArticleОригинальное исследованиеOriginal ResearchЭффективность вакцинации против COVID-19 в организованном коллективе: результаты проспективного исследованияEfficacy of COVID-19 vaccination in organized group: results of a prospective studyСтомаИ. О.StomaI. O.

Игорь Олегович Стома, ректор, д. м. н., доцент

Гомель

Gomel

igor.stoma@gsmu.byКорсакЕ. С.KorsakE. S.

Екатерина Сергеевна Корсак, ассистент

кафедра инфекционных болезней

Гомель

Gomel

katsiaryna.korsak@gsmu.byВоропаевЕ. В.VoropaevE. V.

Евгений Викторович Воропаев, проректор по научной работе, к. м. н., доцент

Гомель

Gomel

voropaev.evgenii@gsmu.byОсипкинаО. В.OsipkinaO. V.

Ольга Викторовна Осипкина, заведующий лабораторией

НИЛ

Гомель

Gomel

olga.osipkina@gsmu.byКовалевА. А.KovalevA. A.

Алексей Алексеевич Ковалев, инженер-программист

отдел науки и научно-методической информации

Гомель

Gomel

aleksey.kovalev@gsmu.byТумашО. Л.TumashO. L.

Оксана Леонидовна Тумаш, доцент кафедры, к. м. н., доцент

кафедра инфекционных болезней

Гомель

Gomel

tumash_ox@gsmu.byРедькоД. Д.RedkoD. D.

Дмитрий Дмитриевич Редько, кандидат медицинских наук, доцент, проректор по лечебной работе, к. м. н., доцент

Гомель

Gomel

dmitriy.redko@gsmu.byГомельский государственный медицинский университетБеларусьGomel State Medical UniversityBelarus2022301220221453540Copyright © Стома И.О., Корсак Е.С., Воропаев Е.В., Осипкина О.В., Ковалев А.А., Тумаш О.Л., Редько Д.Д., 20232023Стома И.О., Корсак Е.С., Воропаев Е.В., Осипкина О.В., Ковалев А.А., Тумаш О.Л., Редько Д.Д.Stoma I.O., Korsak E.S., Voropaev E.V., Osipkina O.V., Kovalev A.A., Tumash O.L., Redko D.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.niidi.ru/jofin/article/view/1424

   Цель: оценить эффективность вакцинации против COVID-19 в организованном коллективе.   Материалы и методы: в исследовании приняли участие 122 взрослых, сотрудников учреждения высшего образования. Участники исследования наблюдались проспективно, а также заполнили анкету, в которой указали возраст, наличие хронических заболеваний, анамнез по COVID-19 и статус вакцинации.   Результаты: участники исследования были разделены на две группы: 59 вакцинированных (48,36 %) и 63 невакцинированных (51,64 %) человека без различий в возрасте между группами. В группе вакцинированных было значительно меньше подтвержденных случаев COVID-19 (р = 0,0008457, df = 1; χ2 = 11,138), значительные различия (p = 0,0084; df = 4; χ2 = 13,678) наблюдались в количестве случаев заболевания среди участников исследования с учетом их статуса вакцинации.   Заключение: участники с диагнозом «Пневмония» в 75 % случаев были невакцинированными (p = 0,00729; df = 1; χ2 =7,2). Все госпитализированные участники исследования были не вакцинированы (p = 0,004678; χ2 =8,0). Ни один из вакцинированных участников не нуждался в респираторной поддержке (p = 0,0455; df = 1; χ2 = 4,0). Хронические заболевания у вакцинированных оказывали значимое (p = 0,04563; df = 2; χ2 = 6,1743) влияние на тяжесть COVID-19.

   Objective: to assess the efficacy of COVID-19 vaccination against in organized group.   Materials and methods: A total of 122 adults, employees of a higher education institution participated in the study. Study participants were observed prospectively and filled out a questionnaire where they indicated their age, presence of chronic diseases, history of COVID-19 and vaccination status.   Findings: the study participants were divided into two groups: 59 vaccinated (48.36 %) and 63 unvaccinated (51.64 %) individuals with no differences in age between the groups. There were significantly fewer confirmed cases of COVID-19 in the vaccinated group (р = 0,0008457, df = 1; χ2 = 11,138), significant differences (p = 0.0084; df = 4; χ2 =13.678) were observed in the number of cases among study participants based on their vaccination status.   Conclusion: participants diagnosed with pneumonia were 75 % unvaccinated (p = 0,00729; df = 1; χ2 = 7,2). All hospitalized study participants were unvaccinated (p = 0,004678; χ2 =8,0). None of the vaccinated participants needed respiratory support (p = 0,0455; df = 1; χ2 = 4,0). Chronic disease in vaccinated subjects made a significant (p = 0,04563; df = 2; χ2 = 6,1743) impact on COVID-19 severity.

вакцинацияCOVID-19SARS-CoV-2vaccinationCOVID-19SARS-CoV-2ReferencesRöltgen K., Nielsen S. C. A., Silva O., Younes S. F., Zaslavsky M., Costales C. et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination // Cell. 2022. Vol. 185 № 6 P.1025-1040.e14. doi: 10.1016/j.cell.2022.01.018Röltgen K., Nielsen S. C. A., Silva O., Younes S. F., Zaslavsky M., Costales C. et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination // Cell. 2022. Vol. 185 № 6 P.1025-1040.e14. doi: 10.1016/j.cell.2022.01.018Nka A. D., Ka’e A. C., Bouba Y., Ngoufack Jagni Semengue E., Tommo Tchouaket M. C., Takou D. et al. Global burden of SARS-CoV-2 infection, hospitalization and case fatality rate among COVID-19 vaccinated individuals and its associated factors: A systematic review and meta-analysis protocol // PLoS One. 2022 Vol. 17 № 8 P. e0272839. doi: 10.1371/journal.pone.0272839Nka A. D., Ka’e A. C., Bouba Y., Ngoufack Jagni Semengue E., Tommo Tchouaket M. C., Takou D. et al. Global burden of SARS-CoV-2 infection, hospitalization and case fatality rate among COVID-19 vaccinated individuals and its associated factors: A systematic review and meta-analysis protocol // PLoS One. 2022 Vol. 17 № 8 P. e0272839. doi: 10.1371/journal.pone.0272839Moghadas S.. M., Vilches T. N., Zhang K., Wells C. R., Shoukat A., Singer B. H., Meyers L. A., Neuzil K. M., Langley J. M., Fitzpatrick M. C., Galvani A. P. The impact of vaccination on COVID-19 outbreaks in the United States // medRxiv [Preprint]. 2021. Vol. 2. P. 2020. 11. 27. 2024 0051. doi: 10.1101/2020.11.27.20240051. Update in: Clinical Infectious Diseases. 2021. Vol. 16 № 73 (12) P. 2257-2264.Moghadas S.. M., Vilches T. N., Zhang K., Wells C. R., Shoukat A., Singer B. H., Meyers L. A., Neuzil K. M., Langley J. M., Fitzpatrick M. C., Galvani A. P. The impact of vaccination on COVID-19 outbreaks in the United States // medRxiv [Preprint]. 2021. Vol. 2. P. 2020. 11. 27. 2024 0051. doi: 10.1101/2020.11.27.20240051. Update in: Clinical Infectious Diseases. 2021. Vol. 16 № 73 (12) P. 2257-2264.Nordström P., Ballin M., Nordström A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden // Lancet. 2022. Vol. 26 № 399 (10327). P. 814-823. doi: 10.1016/S0140-6736(22)00089-7.Nordström P., Ballin M., Nordström A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden // Lancet. 2022. Vol. 26 № 399 (10327). P. 814-823. doi: 10.1016/S0140-6736(22)00089-7.Beeraka N. M, Sukocheva O. A., Lukina E., Liu J., Fan R. Development of antibody resistance in emerging mutant strains of SARS CoV-2: Impediment for COVID-19 vaccines // Reviews in Medical Virology. 2022. P. 13:e2346. Epub ahead of print. doi: 10.1002/rmv.2346.Beeraka N. M, Sukocheva O. A., Lukina E., Liu J., Fan R. Development of antibody resistance in emerging mutant strains of SARS CoV-2: Impediment for COVID-19 vaccines // Reviews in Medical Virology. 2022. P. 13:e2346. Epub ahead of print. doi: 10.1002/rmv.2346.Lee C. J., Woo W., Kim A. Y., Yon D. K., Lee S. W., Koyanagi A. Clinical manifestations of COVID-19 breakthrough infections: A systematic review and meta-analysis // J. Med. Virol. 2022. Vol. 94. № 9. P. 4234–4245. doi: 10.1002/jmv.27871Lee C. J., Woo W., Kim A. Y., Yon D. K., Lee S. W., Koyanagi A. Clinical manifestations of COVID-19 breakthrough infections: A systematic review and meta-analysis // J. Med. Virol. 2022. Vol. 94. № 9. P. 4234–4245. doi: 10.1002/jmv.27871Stepanova M., Lam B., Younossi E., Felix S., Ziayee M., Price J. et al. The impact of variants and vaccination on the mortality and resource utilization of hospitalized patients with COVID-19 // BMC Infect. Dis. 2022. Vol. 22 P. 702. doi: 10.1186/s12879-022-07657-zStepanova M., Lam B., Younossi E., Felix S., Ziayee M., Price J. et al. The impact of variants and vaccination on the mortality and resource utilization of hospitalized patients with COVID-19 // BMC Infect. Dis. 2022. Vol. 22 P. 702. doi: 10.1186/s12879-022-07657-zWickham H., Averick M., Bryan J., Chang W., McGowan L. D., François R., Grolemund G., Hayes A., Henry L., Hester J., Kuhn M., Pedersen T. L., Miller E., Bache S. M., Müller K., Ooms J., Robinson D., Seidel D. P., Spinu V., Takahashi K., Vaughan D., Wilke C., Woo K., Yutani H. Welcome to the tidyverse // Journal of Open Source Software. 2019. Vol. 4 № 43. P. 1686. doi: 10.21105/joss.01686Wickham H., Averick M., Bryan J., Chang W., McGowan L. D., François R., Grolemund G., Hayes A., Henry L., Hester J., Kuhn M., Pedersen T. L., Miller E., Bache S. M., Müller K., Ooms J., Robinson D., Seidel D. P., Spinu V., Takahashi K., Vaughan D., Wilke C., Woo K., Yutani H. Welcome to the tidyverse // Journal of Open Source Software. 2019. Vol. 4 № 43. P. 1686. doi: 10.21105/joss.01686Trajman A., Lachapelle-Chisholm S., Zikos T., Werneck G. L., Benedetti A. Efficacy and effectiveness of SARS-CoV-2 vaccines for death prevention: A protocol for a systematic review and meta-analysis // PLoS One. 2022. Vol. 17 № 7 P. e0265414. doi: 10.1371/journal.pone.0265414Trajman A., Lachapelle-Chisholm S., Zikos T., Werneck G. L., Benedetti A. Efficacy and effectiveness of SARS-CoV-2 vaccines for death prevention: A protocol for a systematic review and meta-analysis // PLoS One. 2022. Vol. 17 № 7 P. e0265414. doi: 10.1371/journal.pone.0265414Rodrigues C. M. C., Plotkin S. A. Impact of Vaccines; Health, Economic and Social Perspectives // Frontiers Microbiology. 2020. Vol. 14 № 11. P. 1526. doi: 10.3389/fmicb.2020.01526.Rodrigues C. M. C., Plotkin S. A. Impact of Vaccines; Health, Economic and Social Perspectives // Frontiers Microbiology. 2020. Vol. 14 № 11. P. 1526. doi: 10.3389/fmicb.2020.01526.Stokel-Walker C. What do we know about covid vaccines and preventing transmission? // BMJ. 2022 Vol. 376. P. o298 doi: 10.1136/bmj.o298Stokel-Walker C. What do we know about covid vaccines and preventing transmission? // BMJ. 2022 Vol. 376. P. o298 doi: 10.1136/bmj.o298Semenzato L., Botton J., Baricault B., Deloumeaux J., Joachim C., Sylvestre E. et al. Vaccine effectiveness against severe COVID-19 outcomes within the French overseas territories: A cohort study of 2-doses vaccinated individuals matched to unvaccinated ones followed up until September 2021 and based on the National Health Data System // PLoS ONE. 2022. Vol. 17 № 9. doi: 10.1371/journal.pone.0274309Semenzato L., Botton J., Baricault B., Deloumeaux J., Joachim C., Sylvestre E. et al. Vaccine effectiveness against severe COVID-19 outcomes within the French overseas territories: A cohort study of 2-doses vaccinated individuals matched to unvaccinated ones followed up until September 2021 and based on the National Health Data System // PLoS ONE. 2022. Vol. 17 № 9. doi: 10.1371/journal.pone.0274309Palmieri L., Floridia M., Giuliano M., Tiple D., Lo Noce C., Meli P. et al. Clinical characteristics of SARS-CoV-2 fullyvaccinated patients dying with COVID-19 in Italy // Clin. Microbiol. Infect. 2022. Vol. 28 № 6 P. 890–892. doi: 10.1016/j.cmi.2022.01.024Palmieri L., Floridia M., Giuliano M., Tiple D., Lo Noce C., Meli P. et al. Clinical characteristics of SARS-CoV-2 fullyvaccinated patients dying with COVID-19 in Italy // Clin. Microbiol. Infect. 2022. Vol. 28 № 6 P. 890–892. doi: 10.1016/j.cmi.2022.01.024Fatima S., Zafar A., Afzal H., Ejaz T., Shamim S., Saleemi S. et al. COVID-19 infection among vaccinated and unvaccinated: Does it make any difference? // PLoS One. 2022. Vol. 17 № 7 P. e0270485. doi: 10.1371/journal.pone.0270485Fatima S., Zafar A., Afzal H., Ejaz T., Shamim S., Saleemi S. et al. COVID-19 infection among vaccinated and unvaccinated: Does it make any difference? // PLoS One. 2022. Vol. 17 № 7 P. e0270485. doi: 10.1371/journal.pone.0270485Vokó Z., Kiss Z., Surján G., Surján O., Barcza Z., Pályi B. et al. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary—the HUN-VE study // Clin. Microbiol. Infect. 2022. Vol. 28 № 3. P.398–404. doi: 10.1016/j.cmi.2021.11.011Vokó Z., Kiss Z., Surján G., Surján O., Barcza Z., Pályi B. et al. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary—the HUN-VE study // Clin. Microbiol. Infect. 2022. Vol. 28 № 3. P.398–404. doi: 10.1016/j.cmi.2021.11.011Vokó Z., Kiss Z., Surján G., Surján O., Barcza Z., Wittmann I. Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study) // Front. Immunol. 2022. Vol. 13 P. 919408. doi: 10.3389/fimmu.2022.919408Vokó Z., Kiss Z., Surján G., Surján O., Barcza Z., Wittmann I. Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study) // Front. Immunol. 2022. Vol. 13 P. 919408. doi: 10.3389/fimmu.2022.919408AlQahtani M., Du X., Bhattacharyya S., Alawadi A., Al Mahmeed H., Al Sayed J. et al. Post-vaccination outcomes in association with four COVID-19 vaccines in the Kingdom of Bahrain // Sci. Rep. 2022. Vol. 12. P. 9236. doi: 10.1038/s41598-022-12543-4AlQahtani M., Du X., Bhattacharyya S., Alawadi A., Al Mahmeed H., Al Sayed J. et al. Post-vaccination outcomes in association with four COVID-19 vaccines in the Kingdom of Bahrain // Sci. Rep. 2022. Vol. 12. P. 9236. doi: 10.1038/s41598-022-12543-4Scutt G., Cross M., Waxman D. Theoretically quantifying the direct and indirect benefits of vaccination against SARS-CoV-2 in terms of avoided deaths. Sci. Rep. 2022. Vol. 12 P. 8833. doi: 10.1038/s41598-022-12591-wScutt G., Cross M., Waxman D. Theoretically quantifying the direct and indirect benefits of vaccination against SARS-CoV-2 in terms of avoided deaths. Sci. Rep. 2022. Vol. 12 P. 8833. doi: 10.1038/s41598-022-12591-w

The authors declare that there are no conflicts of interest present.